DUBLIN, Calif., April 14 SuperGen Inc.(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapiddevelopment and commercialization of therapies for solid tumors andhematological malignancies, today announced as part of a series ofpresentations at the 2008 AACR Annual Meeting that S-110, its DNAmethyltransferase inhibitor, improves in vivo efficacy of decitabine (AbstractNo. 2613).
Entitled, "Decitabine administered as a Dinucleotide prodrug increases itsin vivo efficacy due to enhanced drug delivery and stability," the posterhighlights data indicating that S-110 showed robust anti-tumor activity inprostate and cisplatin-resistant ovarian carcinoma xenograft models.Additionally, S-110 restored sensitivity to cisplatin in the ovarian cancermodel. Importantly, reduced toxicity was observed along with an increasedhalf-life compared to decitabine.
"S-110's increased half-life, reduced toxicity and improvement of efficacywhen compared to decitabine in its currently marketed formulations make it anattractive, next-generation hypomethylator for the treatment of hematoligicmalignancies," said Dr. James Manuso, SuperGen's President and CEO. "As wedevelop S-110 further, we will continue to explore its potential to enhancesolid tumors' sensitivity to standard chemotherapy agents, includingcisplatin. We look forward to advancing this promising candidate to clinicaltrials later this year or early next year."
Copies of the 2008 AACR Annual Meeting poster presentations will beavailable in the pipeline section of SuperGen's Web site www.supergen.com.
Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical companydedicated to the discovery, rapid development and commercialization oftherapies for solid tumors and hematological malignancies. SuperGen isdeveloping a number of therapeutic anticancer products focused on kinase andcell signaling inhibitors and DNA methyltransferase inhibitors. For moreinformation about SuperGen, please visit http://www.supergen.com.
This news release contains certain "forward-looking" statements within themeaning of the Private Securities Litigation Reform Act of 1995. Thesestatements are typically preceded by words such as "believes," "expects,""anticipates," "intends," "will," "may," "should," or similar expressions.These forward-looking statements are not guarantees of future performance andinvolve a number of risks and uncertainties that may cause actual results todiffer materially from the results discussed in these statements. Factorsthat might cause the company's results to differ materially from thoseexpressed or implied by such forward-looking statements include, but are notlimited to, the ability to discover, develop and move target compounds intoclinical development and other risks and uncertainties detailed from time totime in the company's filings with the Securities and Exchange Commissionincluding its most recently filed Form 10-Q and 10-K. SuperGen Inc. undertakesno duty to update any of these forward-looking statements to conform them toactual results.Contacts Timothy L. Enns Mary M. Vegh SuperGen Inc. SuperGen Inc. SVP, Corporate Communications & Business Manager, Investor Development Relations Tel: (925) 560-0100 Tel: (925) 560-2845 E-mail: [email protected]
E-mail: [email protected]
SOURCE SuperGen Inc.